Promising First-Line Therapeutic Approaches for Adult Patients With AML
Eytan Stein, MD, considers promising, new therapeutic options for adult patients with acute myeloid leukemia.
EP: 1.Standard of Care for Newly Diagnosed Adult Patients With AML
EP: 2.Approval of Small Molecular Inhibitors for Patients With AML
EP: 3.First-Line Treatments for Chemotherapy-Ineligible AML
EP: 4.Predictive and Prognostic Factors In Chemotherapy-Ineligible AML
EP: 5.First-Line Treatment Considerations for Chemotherapy-Ineligible AML
EP: 6.Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML
Now Viewing
EP: 7.Promising First-Line Therapeutic Approaches for Adult Patients With AML
EP: 8.Management of Chemotherapy-Ineligible Acute Myeloid Leukemia: Beyond Hypomethylating Agent Monotherapy
Recent Videos
Related Content
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia
Muhammad Hamza Gul, MBBS, MD;Aisha Rehman Siddiqui, MBBS, MD;Farwa Zehra, MBBS;Malaika Rehmani, MBBS;Faraz Waheed, MBBS;Natasha Masood, MBBS;Maleeha Saqib, MBBS;Mahnoor Keen, MBBS, MD;Sharan Siddharth Keshetty, MD;Maham Maqsood, MBBS;Siddharth Arjun Atwal, MD;Muhammad Hamza Sikandari, MBBS;Abdul Baseer Wardak, MBBS
August 19th 2024Article
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
